Do analysts rate SCLX or NRXP?

NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 1,110.53%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NRx Pharmaceuticals 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43

Is SCLX or NRXP more profitable?

NRx Pharmaceuticals has a net margin of -691.81% compared to Scilex's net margin of -1,414.57%. Company Net Margins Return on Equity Return on Assets Scilex -1,414.57% N/A -147.00% NRx Pharmaceuticals -691.81% N/A -63.92%

Do analysts recommend SCLX or VTVT?

vTv Therapeutics has a consensus price target of $55.83, suggesting a potential upside of 79.07%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe vTv Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Do analysts prefer UNCY or SCLX?

Unicycive Therapeutics currently has a consensus target price of $18.25, suggesting a potential upside of 344.04%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend AARD or SCLX?

Aardvark Therapeutics presently has a consensus target price of $13.13, suggesting a potential upside of 175.74%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.36 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate SCLX or LENZ?

LENZ Therapeutics has a consensus price target of $28.80, indicating a potential upside of 691.21%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LENZ Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is SCLX or LENZ more profitable?

LENZ Therapeutics has a net margin of -586.74% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat LENZ Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Scilex -1,414.57% N/A -147.00% LENZ Therapeutics -586.74% -53.39% -49.14%

Scilex (SCLX) Competitors

$2.92 -0.04 (-1.35%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.00 +0.08 (+2.74%)

As of 10/9/2026 07:30 PM Eastern

Compare

SCLX vs. NRXP, VTVT, UNCY, AARD, and LENZ

Should you buy Scilex stock or one of its competitors? Scilex's main competitors and comparable companies include NRx Pharmaceuticals (NRXP), vTv Therapeutics (VTVT), Unicycive Therapeutics (UNCY), Aardvark Therapeutics (AARD), and LENZ Therapeutics (LENZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Scilex compare to NRx Pharmaceuticals?

Scilex (NASDAQ:SCLX) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

NRx Pharmaceuticals has a net margin of -691.81% compared to Scilex's net margin of -1,414.57%.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,414.57%	N/A	-147.00%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

Scilex has a beta of 1.72, indicating that its share price is 72% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market.

NRx Pharmaceuticals has lower revenue, but higher earnings than Scilex. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$31.61M	0.78	-$358.73M	-$49.70	N/A
NRx Pharmaceuticals	$1.23M	100.33	-$28.62M	-$0.55	N/A

NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 1,110.53%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, NRx Pharmaceuticals had 14 more articles in the media than Scilex. MarketBeat recorded 15 mentions for NRx Pharmaceuticals and 1 mentions for Scilex. Scilex's average media sentiment score of 0.00 beat NRx Pharmaceuticals' score of -0.28 indicating that Scilex is being referred to more favorably in the media.

Company	Overall Sentiment
Scilex	Neutral
NRx Pharmaceuticals	Neutral

69.7% of Scilex shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 4.5% of Scilex shares are held by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

NRx Pharmaceuticals beats Scilex on 11 of the 15 factors compared between the two stocks.

How does Scilex compare to vTv Therapeutics?

Scilex (NASDAQ:SCLX) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

vTv Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,414.57%	N/A	-147.00%
vTv Therapeutics	N/A	-6.27%	-5.06%

vTv Therapeutics has a consensus price target of $55.83, suggesting a potential upside of 79.07%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe vTv Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

vTv Therapeutics has lower revenue, but higher earnings than Scilex. vTv Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$31.61M	0.78	-$358.73M	-$49.70	N/A
vTv Therapeutics	$1.02M	120.44	-$26.97M	-$1.06	N/A

69.7% of Scilex shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 4.5% of Scilex shares are held by insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Scilex has a beta of 1.72, indicating that its share price is 72% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

In the previous week, vTv Therapeutics had 11 more articles in the media than Scilex. MarketBeat recorded 12 mentions for vTv Therapeutics and 1 mentions for Scilex. vTv Therapeutics' average media sentiment score of 0.12 beat Scilex's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Scilex	Neutral
vTv Therapeutics	Neutral

Summary

vTv Therapeutics beats Scilex on 12 of the 17 factors compared between the two stocks.

How does Scilex compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 11 more articles in the media than Scilex. MarketBeat recorded 12 mentions for Unicycive Therapeutics and 1 mentions for Scilex. Unicycive Therapeutics' average media sentiment score of 0.05 beat Scilex's score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
Scilex	Neutral

Unicycive Therapeutics has higher earnings, but lower revenue than Scilex. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	N/A	N/A	-$26.56M	-$1.75	N/A
Scilex	$31.61M	0.78	-$358.73M	-$49.70	N/A

Unicycive Therapeutics has a beta of 1.83, indicating that its stock price is 83% more volatile than the broader market. Comparatively, Scilex has a beta of 1.72, indicating that its stock price is 72% more volatile than the broader market.

Unicycive Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Scilex	-1,414.57%	N/A	-147.00%

Unicycive Therapeutics currently has a consensus target price of $18.25, suggesting a potential upside of 344.04%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Unicycive Therapeutics beats Scilex on 11 of the 15 factors compared between the two stocks.

How does Scilex compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Aardvark Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Scilex	-1,414.57%	N/A	-147.00%

Aardvark Therapeutics has a beta of 3.8, suggesting that its share price is 280% more volatile than the broader market. Comparatively, Scilex has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market.

Aardvark Therapeutics has higher earnings, but lower revenue than Scilex. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Scilex	$31.61M	0.78	-$358.73M	-$49.70	N/A

Aardvark Therapeutics presently has a consensus target price of $13.13, suggesting a potential upside of 175.74%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

69.7% of Scilex shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by company insiders. Comparatively, 4.5% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Aardvark Therapeutics had 22 more articles in the media than Scilex. MarketBeat recorded 23 mentions for Aardvark Therapeutics and 1 mentions for Scilex. Aardvark Therapeutics' average media sentiment score of 0.03 beat Scilex's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
Scilex	Neutral

Summary

Aardvark Therapeutics beats Scilex on 12 of the 16 factors compared between the two stocks.

How does Scilex compare to LENZ Therapeutics?

Scilex (NASDAQ:SCLX) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Scilex has a beta of 1.72, indicating that its share price is 72% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

In the previous week, LENZ Therapeutics had 1 more articles in the media than Scilex. MarketBeat recorded 2 mentions for LENZ Therapeutics and 1 mentions for Scilex. Scilex's average media sentiment score of 0.00 equaled LENZ Therapeutics'average media sentiment score.

Company	Overall Sentiment
Scilex	Neutral
LENZ Therapeutics	Neutral

LENZ Therapeutics has a consensus price target of $28.80, indicating a potential upside of 691.21%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

69.7% of Scilex shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 4.5% of Scilex shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

LENZ Therapeutics has a net margin of -586.74% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,414.57%	N/A	-147.00%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

LENZ Therapeutics has lower revenue, but higher earnings than Scilex. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$31.61M	0.78	-$358.73M	-$49.70	N/A
LENZ Therapeutics	$21.48M	5.33	-$82.13M	-$4.09	N/A

Summary

LENZ Therapeutics beats Scilex on 10 of the 15 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCLX vs. The Competition

Export

Metric	Scilex	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.14M	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-0.06	797.58	274.15	26.16
Price / Sales	0.78	757.89	590.50	94.68
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	-0.12	10.71	11.21	6.34
Net Income	-$358.73M	$2.84B	$3.50B	$381.90M
7 Day Performance	-28.08%	-0.93%	-0.90%	-1.41%
1 Month Performance	-42.18%	-4.91%	-4.44%	-3.48%
1 Year Performance	-80.44%	-4.13%	6.96%	1.16%

Scilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCLX Scilex	0.2404 of 5 stars	$2.92 -1.4%	N/A	-83.5%	$25.14M	$31.61M	N/A	34
NRXP NRx Pharmaceuticals	2.0089 of 5 stars	$2.88 +0.2%	$34.50 +1,099.6%	-19.9%	$125.57M	$1.23M	N/A	29	Analyst Revision
VTVT vTv Therapeutics	3.221 of 5 stars	$30.48 +0.5%	$55.83 +83.2%	+36.2%	$120.07M	$36.84M	N/A	26	News Coverage Gap Up
UNCY Unicycive Therapeutics	2.8739 of 5 stars	$4.21 +0.4%	$18.25 +334.0%	-13.1%	$117.11M	$680K	N/A	22
AARD Aardvark Therapeutics	3.0904 of 5 stars	$5.33 +2.1%	$13.13 +146.2%	-71.3%	$116.60M	N/A	N/A	28	Trending News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCLX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scilex (SCLX) Competitors

SCLX vs. NRXP, VTVT, UNCY, AARD, and LENZ

How does Scilex compare to NRx Pharmaceuticals?

Summary

How does Scilex compare to vTv Therapeutics?

Summary

How does Scilex compare to Unicycive Therapeutics?

Summary

How does Scilex compare to Aardvark Therapeutics?

Summary

How does Scilex compare to LENZ Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scilex (SCLX) Competitors

SCLX vs. NRXP, VTVT, UNCY, AARD, and LENZ

How does Scilex compare to NRx Pharmaceuticals?

Is SCLX or NRXP more profitable?

Which has more volatility and risk, SCLX or NRXP?

Which has better earnings & valuation, SCLX or NRXP?

Do analysts rate SCLX or NRXP?

Does the media refer more to SCLX or NRXP?

Do insiders & institutionals believe in SCLX or NRXP?

Summary

How does Scilex compare to vTv Therapeutics?

Is SCLX or VTVT more profitable?

Do analysts recommend SCLX or VTVT?

Which has preferable valuation & earnings, SCLX or VTVT?

Do insiders & institutionals have more ownership in SCLX or VTVT?

Which has more risk and volatility, SCLX or VTVT?

Does the media refer more to SCLX or VTVT?

Summary

How does Scilex compare to Unicycive Therapeutics?

Do insiders & institutionals hold more shares of UNCY or SCLX?

Does the media favor UNCY or SCLX?

Which has stronger valuation and earnings, UNCY or SCLX?

Which has more risk & volatility, UNCY or SCLX?

Is UNCY or SCLX more profitable?

Do analysts prefer UNCY or SCLX?

Summary

How does Scilex compare to Aardvark Therapeutics?

Is AARD or SCLX more profitable?

Which has more risk & volatility, AARD or SCLX?

Which has stronger earnings and valuation, AARD or SCLX?

Do analysts recommend AARD or SCLX?

Do insiders and institutionals hold more shares of AARD or SCLX?

Does the media prefer AARD or SCLX?

Summary

How does Scilex compare to LENZ Therapeutics?

Which has more risk & volatility, SCLX or LENZ?

Does the media favor SCLX or LENZ?

Do analysts rate SCLX or LENZ?

Do insiders & institutionals have more ownership in SCLX or LENZ?

Is SCLX or LENZ more profitable?

Which has preferable earnings & valuation, SCLX or LENZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools